Equity Overview
Price & Market Data
Price: $14.64
Daily Change: -$0.73 / 4.99%
Range: $14.64 - $15.67
Market Cap: $219,778,960
Volume: 143,526
Performance Metrics
1 Week: 34.12%
1 Month: -4.52%
3 Months: 2.32%
6 Months: -69.16%
1 Year: -50.56%
YTD: -32.59%
Company Details
Employees: 107
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.